United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ferndale pharmaceuticals ltd - lidocaine - cutaneous cream - 40mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

healthcare pharma ltd - nitrazepam - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

reckitt benckiser healthcare (uk) ltd - ibuprofen - cutaneous gel - 50mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - lidocaine - cutaneous cream - 40mg/1gram

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - desmopressin acetate - tablets - desmopressin acetate 0.2 mg - desmopressin - central diabetes insipidus.nocturnal enuresis. treatment of nocturia in adults associated with nocturnal polyuria.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 75 mg / 0.83 ml - risankizumab - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of activepsoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - solution (oral) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - solution (oral) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

United States - English - NLM (National Library of Medicine)

idorsia pharmaceuticals ltd - daridorexant (unii: lmq24g57e9) (daridorexant - unii:lmq24g57e9) - quviviq is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see clinical studies (14.1)] . quviviq is contraindicated: - in patients with narcolepsy. - in patients with a history of hypersensitivity to daridorexant or any components of quviviq. angioedema with pharyngeal involvement has been reported [see adverse reactions (6.2)] . pregnancy exposure registry there will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to quviviq during pregnancy. pregnant women exposed to quviviq and healthcare providers are encouraged to call idorsia pharmaceuticals ltd at 1-833-400-9611. risk summary there are no available data on quviviq use in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of daridorexant to pregnant rats and rabbits during the period of organogenesi

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 150 mg / 1 ml - risankizumab - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of activepsoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards).